| News

Basel is “probably the most productive life sciences location in the world”

14.07.2020

Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.

Roche Tower in Basel (img: Mark Niedermann)

The association Interpharma has looked into the Swiss pharma cluster as part of a report and compared it with other international life sciences locations. The Basel Area is described in the report as the “leading pharma region of Switzerland”. According to information contained in the report, at a total of 24.5 billion Swiss francs, the area is responsible for generating two thirds of Switzerland’s pharma value added as a whole.

Numerous companies from the life sciences sector are located within the Basel Region. These include, for example, Novartis, Roche, Actelion, Bayer and Boehringer Ingelheim, among others. These companies not only cover the entire value chain of the pharmaceutical industry, but they are also active in the areas of medtech and biotech as well. According to the report, value added generated by the Basel Area pharma cluster has doubled in real terms over the past decade, with around 6,000 extra jobs having been created within the sector here as well. In 2018, a total of 32,000 people were employed in the life sciences sector in the Basel Area.

Companies located in the Basel Area are also highlighted in the report for being particularly innovative as well. The high intensity of research on the part of these firms is for example, reflected in the number of patent applications. In this context, in 2015, 108 patent applications were registered per million inhabitants in the pharma sector. The Basel pharma cluster, in tandem with Boston, therefore registered the most patent applications per million inhabitants in comparison with other pharma clusters. These top scores have even seen the Basel Region overtake life sciences locations such as the San Francisco Bay Area and Øresund in the area of pharma. According to René Buholzer, CEO of Interpharma, the Basel Region is “probably the most productive life sciences location in the world” overall.

The success of the Basel pharmaceutical sector is attributed to the favourable framework conditions, among other factors, in the report. Moreover, the presence of top-class colleges and universities such as the University of Basel and an offshoot of the Swiss Federal Institute of Technology in Zurich (ETH) also plays a significant role. Last but not least, the region’s proximity to Germany and France, to EuroAirport Basel-Mulhouse-Freiburg as well as to Switzerland’s Rhine ports is additionally highlighted.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Yokogawa establishes innovation center in Allschwil

The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel gains new biotech in Bright Peak

Versant Ventures has made a US$35 million Series A funding commitment to Bright Peak Therapeutics and has now announced the debut of this biotech. It will operate in Basel and San Diego.

Read More
Basel Area Business & Innovation, Innovation, Switzerland Innovation Park

Robots from Basel set to revolutionize surgery

The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.

Read More
Basel Area Business & Innovation, Innovation

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals AG has closed its third financing round, raising over 25 million Swiss francs. The Basel-based startup has developed a bacterial cancer therapy that it now intends to progress to clinical trials.

Read More
Basel Area Business & Innovation, Innovation

Versameb raises 6 million Swiss francs

The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.

Read More
Basel Area Business & Innovation, Innovation

Genedata accelerating drug development

Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Read More
1 2 3 32

Do you have a question? We'd like to hear from you.